Author

Long-Qin Hu

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Editorial Open access Sep 2026

Baxdrostat (Baxfendy®), a first-in-class aldosterone synthase inhibitor approved for adults with uncontrolled hypertension.

Despite the availability of multiple antihypertensive therapies, many patients remain unable to achieve adequate blood pressure control. Excess aldosterone is a key contributor to resistant and uncontrolled hypertension. Baxdrostat (Baxfendy®), a first-in-class selective aldosterone synthase (CYP11B2) inhibitor, was ap...

Ahmed R. Ali, Long-Qin Hu · Medicinal Chemistry Research · 0 citations

Editorial Open access Aug 2026

Zidesamtinib (Jideytro®): a new selective, brain-penetrant ROS1 inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer

ROS1-targeted therapies have improved outcomes in ROS1-positive non-small cell lung cancer (NSCLC), but acquired resistance, CNS progression, and off-target toxicities remain important limitations. Zidesamtinib (Jideytro®, NVL-520) is a next-generation, brain-penetrant, tropomyosin receptor kinase (TRK)-sparing ROS1 in...

Sumi Lee, Long-Qin Hu · Medicinal Chemistry Research · 0 citations